为深化香港另类投资行业的交流与合作，助力香港另类资本市场持续发展，中国人寿海外公司在2025年 成功主办了"香港另类投资策略会——拓展新局，共赢未来"，近800位专家齐聚，探讨另类投资机遇。 香港作为桥头堡的独特地位，为保险资金挖掘另类机会提供广阔空间。此外中国人寿海外公司还定期举 办香港保险资管论坛、投资洞见沟通会、保险资金投资分享会等高端投研活动，汇聚香港头部机构共商 投资策略，有力提升了香港作为国际保险与资管枢纽的地位，促进跨境合作与创新。 中国人寿海外公司通过投资业务拓展、论坛平台搭建等多维度举措，坚定支持香港提升国际金融中心地 位。其作为中资机构的桥头堡作用，将继续深化协同，助力香港金融市场繁荣与国家战略实施，实现共 赢发展。 2025年中国人寿海外公司参与多宗香港H股IPO，支持联交所18A章程（允许未盈利生物科技公司上 市），积极投资半导体、AI、医疗等热点领域企业，支持优秀中资企业在IPO中获得合理定价，繁荣香 港金融市场。中国人寿海外公司通过半导体、AI、医疗等赛道的多只私募股权基金，积极参与到多个 明星创新企业的股权投资，其中部分亮点企业包括： 禾赛科技：全球3D传感器领域的领先者，致力于 ...

Core Insights - The East China Normal University Asia-Europe Business School successfully held the 2025 Corporate Mentor Meet and Appointment Ceremony, officially appointing 41 industry leaders and business elites as the new corporate mentors, marking a significant step in the school's strategy of deepening industry-education integration and collaborative talent cultivation [2] Group 1: Corporate Mentor Program - The corporate mentor program, a core component of the Asia-Europe Business School's "dual mentor system," has successfully held nine sessions to date, aiming to build an efficient communication platform between students and industry leaders, integrating cutting-edge business practices with rigorous academic theories [4] - The program has gathered over 200 corporate mentors and benefited nearly 800 students, serving as an important bridge between campus and industry [4] Group 2: Participation and Industry Coverage - The current corporate mentor program attracted 163 students from 42 countries and regions, with a strong lineup of 41 industry leaders joining or continuing their roles, covering various cutting-edge sectors such as consulting, intelligent manufacturing, marketing, biomedicine, financial services, and information technology [6] - Notably, Xu Xiaopeng, a senior product and technology expert, joined the program, bringing extensive experience from leading roles at Amazon, JD.com, and Ctrip, along with multiple prestigious awards [6] Group 3: Educational Philosophy and Future Directions - The Dean of the Asia-Europe Business School emphasized the need for business education to actively adapt and innovate in the context of artificial intelligence reshaping global business logic, aiming to help students grasp three core learning dimensions: understanding fundamental business logic, deep industry-specific knowledge, and appreciating the human and life values behind business activities [8] - The project director highlighted the corporate mentor program as a key link between academia and the business world, providing students with insights into the real business environment and continuously supplying companies with future leaders possessing international perspectives and excellent professional qualities [10] Group 4: Interactive Engagement - Following the ceremony, students engaged in deep discussions with their mentors across six industry sub-forums, focusing on topics such as industry trends, career development paths, core competency building, and internship opportunities [11] - The Asia-Europe Business School views the corporate mentor program as a strategic initiative to deepen industry-education integration and ensure precise alignment between talent cultivation and industry needs, with plans to continuously invest resources and optimize the program's operations and interaction mechanisms [11]

心玮医疗-B(06609)发布公告，于2026年1月22日，该公司斥资224.3万港元回购4万股。 ...

Core Viewpoint - The article highlights the performance forecasts of Hong Kong-listed companies for the fiscal year 2025, indicating significant growth in sectors such as non-ferrous metals, innovative pharmaceuticals, consumer electronics, and non-bank financials, while traditional agriculture and resource sectors face cyclical pressures [2][16]. Non-Ferrous Metals - The non-ferrous metals sector is a standout performer, with Zijin Mining forecasting a net profit of 51-52 billion yuan for 2025, a year-on-year increase of approximately 59%-62% [4]. - Zijin Gold International expects a net profit of about 1.5-1.6 billion USD, representing a year-on-year increase of approximately 212%-233% [5]. - Chifeng Jilong Gold anticipates a net profit of 3-3.2 billion yuan, up about 70%-81% year-on-year [6]. - Luoyang Molybdenum's forecasted net profit is between 20-20.8 billion yuan, reflecting a growth of 47.8%-53.71% [7]. - The growth in this sector is attributed to rising metal prices and increased production, with Zijin Gold International's gold production expected to rise to approximately 46.5 tons in 2025 from 38.9 tons in 2024 [7]. Innovative Pharmaceuticals - The innovative pharmaceutical sector is also experiencing substantial growth, with Baiaosaitu forecasting a net profit of 135 million yuan, a year-on-year increase of 303.57% [9]. - Zhaoyan New Drug expects a net profit between 233-349 million yuan, reflecting a year-on-year increase of 214%-371% [9]. - WuXi AppTec anticipates a net profit of 19.151 billion yuan, a growth of approximately 103% year-on-year, driven by its integrated CRDMO business model and successful asset sales [10]. Consumer Electronics and Non-Bank Financials - In the consumer electronics sector, QiuTai Technology expects a comprehensive profit increase of approximately 400%-450%, driven by growth in non-mobile smart visual products [12]. - TCL Electronics forecasts an adjusted net profit of 2.33-2.57 billion HKD, representing a growth of 45%-60% year-on-year [12]. - In the non-bank financial sector, China Taiping anticipates a net profit increase of 215%-225%, attributed to improved net investment performance and new tax policies [13]. - Guolian Minsheng expects a net profit of 2.008 billion yuan, a year-on-year increase of approximately 406% due to the acquisition of Minsheng Securities [13]. Traditional Agriculture and Resources - The agriculture sector, represented by Dekang Agriculture, forecasts a profit of 1.3-1.5 billion yuan, a decline from approximately 3.297 billion yuan in the previous year due to falling prices in the pig and chicken markets [14]. - In the resources sector, CITIC Resources expects a net profit of 170-230 million HKD, a decrease of 60%-70% year-on-year, primarily due to falling oil prices and rising raw material costs [14].

Core Insights - The 2026 JPMorgan Healthcare Conference has highlighted significant trends in the biopharmaceutical industry, particularly in mergers and acquisitions (M&A) among multinational corporations (MNCs) [1] - Major acquisitions include Boston Scientific's $14.5 billion purchase of Penumbra and GSK's $2.2 billion acquisition of RAPT Therapeutics, indicating a strong demand for innovative assets [1][6] - The industry is experiencing a "survival of the fittest" phase, with many biotech firms facing operational challenges and some shutting down due to clinical trial failures [2][8] Mergers and Acquisitions - Boston Scientific has announced two major acquisitions: Valencia Technologies Corporation and Penumbra, with the latter being its largest acquisition in nearly 20 years [1][4] - GSK's acquisition of RAPT Therapeutics aims to leverage its global R&D capabilities to enhance the value of RAPT's pipeline [1][6] - The trend of M&A is driven by MNCs facing a "patent cliff," with an estimated $400 billion in revenue at risk over the next decade [4] Industry Dynamics - The demand for high-quality innovative assets is increasing, leading to a surge in business development (BD) and M&A activities in the biopharmaceutical sector [2][4] - The competitive landscape is shifting from product-based competition to pipeline and product integration capabilities among large pharmaceutical companies [7] - Biotech firms are increasingly viewed as valuable partners for MNCs, providing pathways for pipeline realization and cash flow enhancement [2][10] Challenges for Biotech - Nido Biosciences has ceased operations due to clinical trial failures, highlighting the risks faced by biotech companies in the current environment [2][8] - Financial instability and clinical setbacks are common reasons for biotech firms shutting down, with many struggling to secure funding [8][9] - The industry is witnessing a trend where companies must optimize their pipelines and manage resources effectively to survive [9][10] Future Outlook - The biopharmaceutical sector is expected to see continued M&A activity, particularly focusing on late-stage, lower-risk assets as uncertainties in key policies diminish [4] - Chinese biotech firms are increasingly engaging in BD collaborations with MNCs, driven by cost control and R&D efficiency advantages [10][12] - The industry is at a pivotal point, transitioning from quantity-driven growth to a focus on quality and value creation in the global health landscape [12]

Core Insights - The evolving expectations of high-net-worth individuals in China reflect a shift towards personalized and professional wealth management services, emphasizing long-term relationships and trust [1][4] Group 1: Wealth Management Trends - The "2026 China High-Net-Worth Population Wealth Management White Paper" reveals that wealth management now encompasses not just value preservation and growth, but also intergenerational transfer, corporate strategy, and overall life planning [1][4] - High-net-worth individuals exhibit diverse characteristics in client structure, risk preferences, and service needs, necessitating tailored solutions from financial institutions [4][7] Group 2: Risk Preferences and Service Needs - A notable finding is the "inverted U-shaped" risk preference curve among high-net-worth individuals, with older generations (70s and 80s) being more risk-tolerant compared to younger generations (90s) and those from the 60s, who show higher risk aversion [9][10] - Service preferences vary by generation, with older clients valuing sincere service and long-term relationships, while younger clients prioritize the competence and communication skills of their advisors [9][10] Group 3: Asset Allocation Behavior - High-net-worth individuals prioritize a "steady first, attack and defend" approach in asset allocation, primarily holding financial products, deposits, and insurance, while over 30% also invest in stocks for enhanced returns [10] - There is a significant intention among over half of high-net-worth individuals to increase their holdings in financial products and cash deposits in the coming year, while opinions on stock investments are divided [10] Group 4: Service Demand and Brand Expectations - The core demands of high-net-worth individuals from private banks include personalization, professionalism, and security, with over 50% highlighting these aspects as essential [10] - The highest mention rate for "personalization" at 44.3% indicates a strong expectation for customized solutions and exclusive experiences from wealth management institutions [10] Group 5: Entrepreneurial Needs and Cross-Border Services - The needs of entrepreneurs within the high-net-worth demographic are driving the expansion of private banking services, requiring customized solutions that align personal wealth management with corporate cycles and strategies [11] - A significant 56.6% of surveyed entrepreneurs express a need for cross-border services related to trade finance, global investment, and capital management, particularly those with 30% to 50% of personal assets held overseas [11] Group 6: Integrated Solutions from Financial Institutions - China Bank's "China Bank Solution" aims to address the complex and diverse needs of high-net-worth individuals by integrating various financial services across domestic and international lines [12] - The "Entrepreneur Office" service model showcases China Bank's ability to cater to the intertwined needs of personal and corporate wealth management, exemplified by a case involving a biopharmaceutical company preparing for an IPO [14][15] Group 7: Wealth Transfer and Philanthropy - China Bank provides flexible and systematic tools for family wealth transfer, including insurance trusts that ensure asset transmission while isolating risks [16] - The bank's approach to charitable trusts illustrates its commitment to facilitating sustainable philanthropic efforts, ensuring that clients' charitable intentions are legally upheld and financially viable [15][16] Group 8: Cross-Border Investment Challenges - High-net-worth individuals face significant challenges in cross-border asset allocation, including a lack of understanding of foreign investment product regulations and limited access to quality products and professional advice [16] - China Bank leverages its global network and comprehensive financial product offerings to provide compliant cross-border investment channels and expert market insights [16]

中新网武汉1月22日电 湖北省"51020"先进制造业集群产业生态之医工交叉产业对接活动22日在武汉举 行，湖北省医工交叉融合创新产业联盟正式揭牌成立，31项医工交叉融合创新项目及产业化项目达成合 作，意向投资总额约12亿元，涉及医工交叉产业全链条合作，涵盖产学研医融全生态协同。 湖北省医工交叉融合创新产业联盟，是在湖北省经信厅、湖北省卫健委、湖北省药监局等部门指导下组 建的省级医工融合创新转化平台。该联盟汇聚医疗机构、高校院所、投融资机构、医药龙头及专业服务 机构等多家核心单位，构建起"临床需求—技术研发—中试熟化—资本赋能—产业落地"的全链条创新生 态体系。 现场，湖北省2025年医工交叉揭榜挂帅十大创新项目正式发布。湖北省经信厅将对揭榜项目给予最高 500万元资金扶持，推动创新链、产业链、资金链深度融合，加速以生物医药为核心的大健康产业高质 量发展。(完) （文章来源：中国新闻网） 湖北省医工交叉融合创新产业联盟理事长马丁表示，联盟将动员平台机构和医药企业力量，聚焦科创成 果转化早介入、早对接、早融合，在概念验证、中试熟化、临床研究、法规认证、产业化等各环节进行 孵化，培育更多医疗创新型科技企业，不断壮 ...

Market Performance - On January 22, the A-share market experienced a morning surge followed by a pullback, with the three major indices closing in the green, and the ChiNext Index rising nearly 1% [1][6] - The ChiNext 50 ETF (159949) increased by 1.04%, closing at 1.558 yuan, with a turnover rate of 5.20% and a transaction volume of 1.299 billion yuan, ranking first among similar ETFs [1][6] Liquidity and Trading Data - As of January 22, the ChiNext 50 ETF (159949) recorded a cumulative transaction amount of 38.006 billion yuan over the last 20 trading days, with an average daily transaction amount of 1.900 billion yuan; since the beginning of the year, the cumulative transaction amount over 14 trading days was 27.332 billion yuan, with an average daily transaction amount of 1.952 billion yuan [2][7] - The circulating scale of the ChiNext 50 ETF was 24.900 billion yuan as of January 21, 2026 [2][7] Fund Holdings and Performance - The latest quarterly report indicates that the top ten holdings of the ChiNext 50 ETF (159949) showed mixed performance, including stocks like CATL, Zhongji Xuchuang, and Mindray Medical [3][8] - The fund manager noted that the fourth quarter saw a return to structural market trends, with significant divergence in the ChiNext, particularly in sectors like AI and new energy [10] Investment Outlook - The ChiNext 50 ETF is viewed as a convenient tool for long-term investors interested in China's technology growth sector, with a three-year return of 35.16%, outperforming its benchmark and ranking 526th among 1,633 similar products [5][11] - Recommendations for investors include adopting a dollar-cost averaging strategy or phased investment to smooth out short-term volatility while closely monitoring the performance of constituent stocks and relevant policy developments [5][11]

金陵之冬，创意满城。 紫金山科技城开启"6G迎新派对"，机甲麒麟在繁华商圈"赛博"起舞，牛首山2026架无人机绘出马年元 素……辞旧迎新之际，南京举办128场跨年活动，刷新地铁单日运力纪录，带动元旦旅游消费增长显 著。 被科技点亮的夜空，不仅映照城市温度、治理精度，更展现烟火寻常、活力日常。"创新敢为才能破圈 出彩。"一位网民在"南京发布"留言。 立足产业强市之要，南京做好"转强增育"四篇文章，构筑新质生产力主导的产业高地。 ——"转"型攀峰，传统产业固本开新。入选国家首批领航级智能工厂的南京钢铁集团，上万个传感器如 同"智能神经元"遍布产线。一笔耐磨钢订单刚录入系统，"元冶·钢铁大模型"30秒内即算出最佳生产方 案。"从'经验炼钢'钢花飞溅到'智慧炼钢'数据奔流，铁水罐周转率提升5%，每吨铁水降本200元，仅此 一项每年就节省上亿元。"南钢副总裁朱平说。 面向"十五五"，南京将实施传统产业攀峰计划，推动石化、钢铁等产业向价值链中高端迈进，力争 到"十五五"末，化工新材料占石化产业40%，优特钢占钢铁制造超80%。 ——登高做"强"，新兴产业集群跃升。20世纪60年代，东南大学的查礼冠教授团队，仅凭两张机器人 ...

Core Viewpoint - The company, 宜明昂科-B, has seen a stock increase of over 5% following the announcement of successful patient recruitment for a Phase III clinical trial of IMM01 for chronic myelomonocytic leukemia (CMML) treatment, indicating positive momentum in its clinical development and potential future partnerships [1] Group 1: Clinical Development - The company announced the successful recruitment of 104 patients for the Phase III clinical trial of IMM01, aimed at treating CMML, with expectations to complete recruitment of 132 patients by the end of March 2026 [1] - The company plans to submit a pre-BLA application by the end of 2026 and is advancing its research in atherosclerosis to the concept validation stage [1] Group 2: Business Operations - As of the announcement date, the board confirmed that the company's business operations and clinical development remain normal, with no significant adverse changes in the financial status [1] Group 3: Industry Engagement - The company participated in the 44th J.P. Morgan Healthcare Conference, where its founder and CEO, Dr. Tian Wenzhi, presented the company's development status and key project progress [1] - During the conference, the executive team engaged with over ten multinational pharmaceutical and biotechnology companies, establishing deep communication with several potential partners, which is expected to lead to substantial progress in 2026 [1]